SEC Form 4 · accession 0001209191-16-096726
NEUROCRINE BIOSCIENCES INC · NBIX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Malcolm Lloyd-Smith
Officer — Chief Regulatory Officer
Period of report
Feb 5, 2016
Accepted (ET)
Feb 9, 2016 · 4:22 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000914475
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitF1,F2 | — | Feb 5, 2016 | A | 7,700 | A | — | — | Common Stock | 7,700 | 7,700 | D |
| Stock OptionF3 | $35.99 | Feb 5, 2016 | A | 36,400 | A | — | Feb 5, 2026 | Common Stock | 36,400 | 36,400 | D |
| Restricted Stock UnitF1,F4 | — | Feb 5, 2016 | A | 20,500 | A | — | Feb 5, 2020 | Common Stock | 20,500 | 20,500 | D |
Explanation of responses
- F1Each Restricted Stock Unit represents a contingent right to receive one share of the Neurocrine Common Stock.
- F2The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 5, 2017, February 5, 2018, February 5, 2019, and February 5, 2020.
- F3Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 5, 2016 and an additional 1/48th of the shares underlying the option becomes vested and excercisable each month thereafter.
- F4Performance Restricted Stock Units ("PRSU") will vest upon the date the Company has achieved both (1) obtaining positive pivotal clinical trial data for the treatment of Tourette syndrome with valbenazine and (2) FDA acceptance of a New Drug Application for the treatment of Tourette syndrome with valbenazine.